Market By Type, Technology, Age Group, Delivery Mode And Geography | Forecast 2019-2028
After a detailed analysis, Triton Market Research has concluded that the influenza vaccines market is expected to display an upward trend and is estimated to grow at a CAGR of 6.20% in terms of revenue over the forecast period of 2019 to 2028. The market was valued at $4114.53 million in 2019, and is anticipated to reach $7070.90 million by the year 2028.
Report scope can be customized per your requirements. Request For Customization
Influenza is a major health concern in many countries that causes seasonal epidemics in temperate regions and year-round epidemics in some of the tropical regions. Influenza viruses affect mainly the upper and/or lower respiratory tract. These viruses constantly change, and hence it becomes necessary for changing the vaccines strain annually to match with the strain currently in circulation globally. Influenza vaccination holds importance as it minimizes the possibility of adverse effects on public health. The necessity has further increased due to the onset of Wuhan originated Covid-19 virus at the start of the year 2020 across the globe. With the use of the influenza vaccine, the governments globally want to reduce the pressure on healthcare infrastructure already caused due to the coronavirus spread.
Within this report from Triton Market Research on the influenza vaccines market, the market definition and the key insights regarding the industry are discussed. Also, the market attractiveness matrix, vendor scorecard and Porter’s five force analysis are studied for the influenza vaccine industry.
The advancement in technology, coupled with the initiatives taken up by the government, are the major factors driving the growth of the global influenza vaccines market. However, market growth is restrained by the high cost involved in developing the vaccine. Other factors, like complex development processes, are also challenging the industry at this moment. But, key opportunities, like the growth in cases of influenza, can be an opportunity for the market to get towards the projected growth.
Geographies covered for global influenza vaccine market:
• North America: United States and Canada
• Europe: United Kingdom, Germany, France, Italy, Spain, Russia and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, ASEAN countries, Australia & New Zealand and Rest of Asia-Pacific
• Latin America: Brazil, Mexico and Rest of Latin America
• Middle East and Africa: United Arab Emirates, Turkey, Saudi Arabia, South Africa and Rest of Middle East & Africa
The influenza vaccines market is segmented as follows:
• Market by type:
o Quadrivalent
o Trivalent
• Market by technology:
o Egg-based
o Trivalent
• Market by age group:
o Pediatric
o Adult
• Market by delivery mode:
o Injection
o Nasal Spray
Some of the prominent players in the influenza vaccine market are Sanofi, Pfizer Inc, GlaxoSmithKline Plc, BioDiem, Novartis AG, F. Hoffmann-La Roche Ltd, Merck Sharp & Dohme Corp, Abbott, Emergent Biosolutions Inc and CSL Limited.
The strategic analysis for each of these companies in the influenza vaccine market is covered in detail. Company profiles help to dive into the information about the key market players in this industry and how much hold they have on the market. The immense growth opportunities are attracting new companies to rush into the market, and thus accelerate the degree of competition.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL INFLUENZA VACCINES MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. QUADRIVALENT IS THE DOMINANT TYPE OF INFLUENZA VACCINE
2.2.2. INJECTION IS FASTEST-GROWING DELIVERY MODE
2.2.3. CELL-BASED TECHNOLOGY IS RAPIDLY GROWING TECHNOLOGY IN THE MARKET
2.2.4. ADULT AGE GROUP IS MAJORLY CONTRIBUTING IN THE MARKET
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE
2.3.3. BARGAINING POWER OF SUPPLIERS
2.3.4. BARGAINING POWER OF BUYERS
2.3.5. INTENSITY OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1. ADVANCEMENT IN TECHNOLOGY
2.6.2. INITIATIVES TAKEN UP BY THE GOVERNMENT
2.7. MARKET RESTRAINTS
2.7.1. HIGH COST OF DEVELOPMENT
2.8. MARKET OPPORTUNITIES
2.8.1. GROWTH IN THE CASES OF INFLUENZA
2.9. MARKET CHALLENGES
2.9.1. COMPLEX DEVELOPMENT PROCESS
3. INFLUENZA VACCINES MARKET OUTLOOK - BY TYPE
3.1. QUADRIVALENT VACCINE
3.2. TRIVALENT VACCINE
4. INFLUENZA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
4.1. EGG-BASED TECHNOLOGY
4.2. CELL-BASED TECHNOLOGY
5. INFLUENZA VACCINES MARKET OUTLOOK - BY AGE GROUP
5.1. PEDIATRIC AGE GROUP
5.2. ADULT AGE GROUP
6. INFLUENZA VACCINES MARKET OUTLOOK - BY DELIVERY MODE
6.1. INJECTION
6.2. NASAL SPRAY
7. INFLUENZA VACCINES MARKET – REGIONAL OUTLOOK
7.1. NORTH AMERICA
7.1.1. MARKET BY TYPE
7.1.2. MARKET BY TECHNOLOGY
7.1.3. MARKET BY AGE GROUP
7.1.4. MARKET BY DELIVERY MODE
7.1.5. COUNTRY ANALYSIS
7.1.5.1. UNITED STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1. MARKET BY TYPE
7.2.2. MARKET BY TECHNOLOGY
7.2.3. MARKET BY AGE GROUP
7.2.4. MARKET BY DELIVERY MODE
7.2.5. COUNTRY ANALYSIS
7.2.5.1. UNITED KINGDOM
7.2.5.2. GERMANY
7.2.5.3. FRANCE
7.2.5.4. SPAIN
7.2.5.5. ITALY
7.2.5.6. RUSSIA
7.2.5.7. REST OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. MARKET BY TYPE
7.3.2. MARKET BY TECHNOLOGY
7.3.3. MARKET BY AGE GROUP
7.3.4. MARKET BY DELIVERY MODE
7.3.5. COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. INDIA
7.3.5.4. SOUTH KOREA
7.3.5.5. ASEAN COUNTRIES
7.3.5.6. AUSTRALIA & NEW ZEALAND
7.3.5.7. REST OF ASIA-PACIFIC
7.4. LATIN AMERICA
7.4.1. MARKET BY TYPE
7.4.2. MARKET BY TECHNOLOGY
7.4.3. MARKET BY AGE GROUP
7.4.4. MARKET BY DELIVERY MODE
7.4.5. COUNTRY ANALYSIS
7.4.5.1. BRAZIL
7.4.5.2. MEXICO
7.4.5.3. REST OF LATIN AMERICA
7.5. MIDDLE EAST AND AFRICA
7.5.1. MARKET BY TYPE
7.5.2. MARKET BY TECHNOLOGY
7.5.3. MARKET BY AGE GROUP
7.5.4. MARKET BY DELIVERY MODE
7.5.5. COUNTRY ANALYSIS
7.5.5.1. THE UNITED ARAB EMIRATES
7.5.5.2. TURKEY
7.5.5.3. SAUDI ARABIA
7.5.5.4. SOUTH AFRICA
7.5.5.5. REST OF MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. MERCK SHARP & DOHME CORP
8.2. NOVARTIS AG
8.3. PFIZER INC
8.4. SANOFI
8.5. BIODIEM
8.6. EMERGENT BIOSOLUTIONS INC
8.7. F. HOFFMANN-LA ROCHE LTD
8.8. GLAXOSMITHKLINE PLC
8.9. ABBOTT
8.10. CSL LIMITED
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.1.1. OBJECTIVES OF STUDY
9.1.2. SCOPE OF STUDY
9.2. SOURCES OF DATA
9.2.1. PRIMARY DATA SOURCES
9.2.2. SECONDARY DATA SOURCES
9.3. RESEARCH METHODOLOGY
9.3.1. EVALUATION OF PROPOSED MARKET
9.3.2. IDENTIFICATION OF DATA SOURCES
9.3.3. ASSESSMENT OF MARKET DETERMINANTS
9.3.4. DATA COLLECTION
9.3.5. DATA VALIDATION & ANALYSIS
TABLE 1: GLOBAL INFLUENZA VACCINES MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: GLOBAL INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 4: GLOBAL INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 5: GLOBAL INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 6: GLOBAL INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 7: GLOBAL INFLUENZA VACCINES MARKET, BY GEOGRAPHY, 2019-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 13: EUROPE INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 14: EUROPE INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 15: EUROPE INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 16: EUROPE INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 17: EUROPE INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 18: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 19: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 20: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 23: LATIN AMERICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 24: LATIN AMERICA INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 25: LATIN AMERICA INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 26: LATIN AMERICA INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 28: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 29: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 30: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 31: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 32: MIDDLE EAST AND AFRICA INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
FIGURE 1: GLOBAL INFLUENZA VACCINES MARKET, BY SOURCE, 2019 & 2028 (IN %)
FIGURE 2: GLOBAL QUADRIVALENT INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 3: GLOBAL INJECTION DELIVERY MODEL MARKET, 2019-2028 (IN $ MILLION)
FIGURE 4: GLOBAL CELL-BASED TECHNOLOGY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 5: GLOBAL ADULT AGE GROUP MARKET, 2019-2028 (IN $ MILLION)
FIGURE 6: PORTER’S FIVE FORCE ANALYSIS
FIGURE 7: MARKET ATTRACTIVENESS INDEX
FIGURE 8: GLOBAL INFLUENZA VACCINES MARKET, BY QUADRIVALENT VACCINE, 2019-2028 (IN $ MILLION)
FIGURE 9: GLOBAL INFLUENZA VACCINES MARKET, BY TRIVALENT VACCINES, 2019-2028 (IN $ MILLION)
FIGURE 10: GLOBAL INFLUENZA VACCINES MARKET, BY EGG-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 11: GLOBAL INFLUENZA VACCINES MARKET, BY CELL-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: GLOBAL INFLUENZA VACCINES MARKET, BY PEDIATRIC AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 13: GLOBAL INFLUENZA VACCINES MARKET, BY ADULT AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 14: GLOBAL INFLUENZA VACCINES MARKET, BY INJECTION, 2019-2028 (IN $ MILLION)
FIGURE 15: GLOBAL INFLUENZA VACCINES MARKET, BY NASAL SPRAY, 2019-2028 (IN $ MILLION)
FIGURE 16: GLOBAL INFLUENZA VACCINES MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 17: UNITED STATES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: CANADA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 19: UNITED KINGDOM INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 20: GERMANY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 21: FRANCE INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 22: SPAIN INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 23: ITALY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 24: RUSSIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 25: REST OF EUROPE INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 26: CHINA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 27: JAPAN INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 28: INDIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 29: SOUTH KOREA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 30: ASEAN COUNTRIES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 31: AUSTRALIA & NEW ZEALAND INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 32: REST OF ASIA-PACIFIC INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 33: BRAZIL INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 34: MEXICO INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 35: REST OF LATIN AMERICA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 36: THE UNITED ARAB EMIRATES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 37: TURKEY INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 38: SAUDI ARABIA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 39: SOUTH AFRICA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 40: REST OF MIDDLE EAST & AFRICA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)